-
In 2003, he became head of the Netherlands Proteomics Biological Research Center at the UMC Utrecht.
-
Since 2012, he has been head of Basal Research at the Center for Lysosomal and Metabolic Diseases at the Erasmus MC in Rotterdam.
-
In 2023, he became the unpaid scientific director of LentiCure. Thanks to Spierziekten Nederland and the Prinses Beatrix Spierfonds, he was appointed special professor of 'Cell and gene therapy'.
You can find more information on Linked-In
Pim Pijnappel is also medical advisor of the diagnostic working group Congenital and metabolic muscle diseases of Spierziekten Nederland and an expert in Pompe disease. His team is preparing a clinical study with gene therapy for this hereditary muscle disease. They use the bone marrow as an ‘enzyme factory’ to treat the disease. The start-up LentiCure plays a crucial role in bringing this therapy to the market, which can probably also be used for other rare diseases.
About Pim Pijnappel
Pim Pijnappel is known for his great commitment and expertise. He is determined to find new treatments for serious (rare) diseases through advanced research:
“From a young age, I have been interested, no fascinated, by the processes in the human body. I want to know how they work and how you can respond to them. I want to help patients and correct errors in the human body”.
With the founding of LentiCure and his focus on the development of gene therapy, he – and his team of scientists – are contributing to the development of practical, effective and affordable treatments for complex diseases.
"My goal is to use the potential of stem cells and genome engineering to develop new treatments for previously unsolvable diseases."